Thus, this effect can be ascribed to the anti-angiogenic agents. when bevacizumab was combined with chemotherapy in first-line setting. This was recently confirmed by Manegold (2008). Moreover, a phase I/II trial combining the epidermal growth factor receptor (EGFR) inhibitor erlotinib…